Open Nav

Fusion Pharmaceuticals Inc.

  • John Valliant, Fusion Pharmaceuticals Inc.

To introduce our company and lead product

  • Date:Thursday, October 18
  • Time:10:00 AM - 10:15 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Fusion is a clinical stage company focused on developing novel targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers. Our first product, FPX-01, combines the precise targeting of a human experienced antibody with Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 to induce cancer cell death. A clinical trial on FPX-01 is planned for early 2018.
  • Company Website:
  • Company HQ City:Hamilton
  • Company HQ Country:Canada
  • Company HQ State:Ontario
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :FPI-1434
  • Development Phase of Primary Product:Phase I
  • Total Amount Raised to Date, In All Rounds:$46M USD
John Valliant
Fusion Pharmaceuticals Inc.